Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Business Wire

Submitted by Anonymous (not verified) on Tue, 08/30/2022 - 12:00

Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder  Business Wire